PT010
As of the edition of 20 October 2026, PT010 is a drug known only by a code name: went quiet in 2017; acts on ADRB2, CHRM1 and CHRM2 and 4 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2017
- Kind
- Code name only
- Registered trials
- 4, 0 stopped early
- Disease areas
- Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
7 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product7 company-target rows are on route A because of PT010.
See the 7 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| NR3C1 | Glucocorticoid receptor | P04150 |
| ADRB2 | Beta-2 adrenergic receptor | P07550 |
| CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 |
| CHRM4 | Muscarinic acetylcholine receptor M4 | P08173 |
| CHRM5 | Muscarinic acetylcholine receptor M5 | P08912 |
| CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 |
| CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pearl Therapeutics | Lead sponsor of trials | 2014 to now |